Development and validation of rapid and sensitive HPLC method for the quantitative determination of doxorubicin in human plasma

References

• Gan MO, Ryoho TK. Adriamycin (doxorubicin). Jap J Cancer Chemo 2001;28:1331–1338.
   Google Scholar
• Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761–2765.
   PubMed Web of Science ®Google Scholar
• Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001;28:2–7.
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931–936.
   PubMed Web of Science ®Google Scholar
• Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001;61:8422–8428.
   PubMed Web of Science ®Google Scholar
• Wang GX, Wang YX, Zhou XB, Korth M. Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 2001;423:99–107.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, Redmond MD. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 1993;13:1945–1952.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Bachur NR. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 1976;4:79–87.
   PubMed Web of Science ®Google Scholar
• Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Possati G. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 1995;95:1595–1605.
   PubMed Web of Science ®Google Scholar
• Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 2000;13:414–420.
   PubMed Web of Science ®Google Scholar
• Camaggi CM, Comparsi R, Strocchi E, Testoni F, Pannuti F. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 1988;21:216–220.
   PubMed Web of Science ®Google Scholar
• Nicholls G, Clark BJ, Brown JE. Solid-phase extraction and optimized separation of doxorubicin, epirubicin and their metabolites using reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1992;10:949–957.
   PubMed Web of Science ®Google Scholar
• van Asperen J, van Tellingen O, Beijnen JH. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;712:129–143.
   PubMedGoogle Scholar
• Beijnen JH, Meenhorst PL, van Gijn R, Fromme M, Rosing H, Underberg WJ. HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. J Pharm Biomed Anal 1991;9:995–1002.
   PubMed Web of Science ®Google Scholar
• Andersen A, Warren DJ, Slordal L. A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 1993;15:455–461.
   PubMed Web of Science ®Google Scholar
• de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999;266:216–221.
   PubMed Web of Science ®Google Scholar
• Zhao P, Dash AK. A simple HPLC method using a microbore column for the analysis of doxorubicin. J Pharm Biomed Anal 1999;20:543–548.
   PubMed Web of Science ®Google Scholar
• Chin DL, Lum BL, Sikic BI. Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet–visible high-performance liquid chromatography. J Chromatography B 2002;779:259–269.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RR, Pittman KA, Spector S. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309–312.
   Web of Science ®Google Scholar
• Kumar VS, Kaushik HK, Kumar SB. Population pharmacokinetics of doxorubicin in Indian cancer patients using NONMEM. Clinical Research and Regulatory Affairs 2009;26(4):93–100.
   Google Scholar
• Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet P-J, Court-Fortune I, Riou R, Rebattu P, Boissel J-P, Trillet-Lenoir V & Girard P. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. Ther Drug Monit 1999;21:367.
   PubMed Web of Science ®Google Scholar
• Reddy LH, Meda N, Murthy RR. Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood—the silver nitrate artefact. Acta Pharm (Zagreb, Croatia) 2005;55:81–91.
   PubMedGoogle Scholar
• Fahmy OT, Korany MA, Maher HM. High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma. J Pharm Biomed Anal 2004;34:1099–1107.
   PubMed Web of Science ®Google Scholar